DK1425270T3 - Fremgangsmåder og intermediater til fremstilling af 4-aminoquinolin CETP inhibitorer - Google Patents

Fremgangsmåder og intermediater til fremstilling af 4-aminoquinolin CETP inhibitorer

Info

Publication number
DK1425270T3
DK1425270T3 DK02722567T DK02722567T DK1425270T3 DK 1425270 T3 DK1425270 T3 DK 1425270T3 DK 02722567 T DK02722567 T DK 02722567T DK 02722567 T DK02722567 T DK 02722567T DK 1425270 T3 DK1425270 T3 DK 1425270T3
Authority
DK
Denmark
Prior art keywords
aminoquinoline
intermediates
preparation
methods
cetp inhibitors
Prior art date
Application number
DK02722567T
Other languages
Danish (da)
English (en)
Inventor
David Burns Damon
Robert Wayne Dugger
Robert William Scott
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1425270T3 publication Critical patent/DK1425270T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK02722567T 2001-04-30 2002-04-08 Fremgangsmåder og intermediater til fremstilling af 4-aminoquinolin CETP inhibitorer DK1425270T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28752201P 2001-04-30 2001-04-30

Publications (1)

Publication Number Publication Date
DK1425270T3 true DK1425270T3 (da) 2006-07-03

Family

ID=23103272

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02722567T DK1425270T3 (da) 2001-04-30 2002-04-08 Fremgangsmåder og intermediater til fremstilling af 4-aminoquinolin CETP inhibitorer
DK02722569T DK1383734T3 (da) 2001-04-30 2002-04-08 Forbindelser, der er anvendelige som mellemprodukter til 4-aminoquinolinderivater

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02722569T DK1383734T3 (da) 2001-04-30 2002-04-08 Forbindelser, der er anvendelige som mellemprodukter til 4-aminoquinolinderivater

Country Status (25)

Country Link
US (3) US6600045B2 (de)
EP (2) EP1425270B1 (de)
JP (2) JP3924250B2 (de)
KR (2) KR100591998B1 (de)
CN (3) CN100357265C (de)
AR (3) AR036331A1 (de)
AT (2) ATE321755T1 (de)
AU (1) AU2002253448B2 (de)
BR (2) BR0209291A (de)
CA (2) CA2445693A1 (de)
CZ (2) CZ20032898A3 (de)
DE (2) DE60210265T2 (de)
DK (2) DK1425270T3 (de)
ES (2) ES2256461T3 (de)
HK (1) HK1062294A1 (de)
HU (2) HU225777B1 (de)
IL (2) IL157544A0 (de)
MX (2) MXPA03009936A (de)
PL (2) PL366700A1 (de)
PT (1) PT1425270E (de)
RU (2) RU2265010C2 (de)
TW (1) TWI250974B (de)
WO (2) WO2002088085A2 (de)
YU (2) YU84303A (de)
ZA (2) ZA200306600B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US20040002615A1 (en) * 2002-06-28 2004-01-01 Allen David Robert Preparation of chiral amino-nitriles
JP2006021999A (ja) * 2002-07-12 2006-01-26 Kaneka Corp 光学活性β−アミノニトリル化合物およびその対掌体アミド化合物の製造方法
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7211672B2 (en) * 2002-10-04 2007-05-01 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
EP1961419B1 (de) 2002-12-20 2010-03-24 Pfizer Products Inc. Dosierungsform enthaltend einen CETP-Hemmer und einen HMG-CoA Reduktase Hemmer
WO2004074255A2 (en) * 2003-02-18 2004-09-02 Takasago International Corporation Method for producing an optically active tetrahydroquinoline
EP1604975A4 (de) * 2003-03-17 2006-11-02 Kaneka Corp Verfahren zur herstellung von (r)-3-¬4-(trifluormethyl)phenylamino)pentanamidderivaten
US7223859B2 (en) 2003-03-17 2007-05-29 Pfizer Inc. Method for producing (R)-3-[4-(trifluoromethyl) phenylamino]-pentanoic acid amide derivative
SG146695A1 (en) 2003-09-26 2008-10-30 Japan Tobacco Inc Method of inhibiting remnant lipoprotein production
EP2098512A1 (de) * 2003-10-08 2009-09-09 Eli Lilly & Company Verbindungen und Verfahren zur Behandlung von Dyslipidämie
DE602004020649D1 (de) * 2003-11-07 2009-05-28 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
RU2006138603A (ru) * 2004-04-07 2008-05-20 Милленниум Фармасьютикалз, Инк. (Us) Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
US20080269284A1 (en) * 2004-06-24 2008-10-30 Eli Lilly And Company Compounds and Methods for Treating Dyslipidemia
DE102004031656A1 (de) * 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
WO2006069162A1 (en) * 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
AU2006216713A1 (en) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20100041911A1 (en) * 2005-06-20 2010-02-18 Astrazeneca Ab Process For The Production Of (Alkoxycarbonylamino)alkyl Sulfonates
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
DE102006031143A1 (de) * 2006-07-04 2008-01-24 Merck Patent Gmbh Fluortenside
DE102006031149A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031262A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006032391A1 (de) * 2006-07-04 2008-01-17 Merck Patent Gmbh Fluortenside
DE102006031151A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
EP2134169A2 (de) 2007-03-09 2009-12-23 Indigene Pharmaceuticals Inc. Kombination von metformid-r-(+)-lipoat und antihyperlipidämika für die behandlung von diabetes-hyperglykämie und diabetesbedingte komplikationen
JP2011256110A (ja) * 2008-09-30 2011-12-22 Takeda Chem Ind Ltd ヘキサヒドロピロロキノリンの製造法
TWI450896B (zh) 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
ES2617221T3 (es) 2011-04-12 2017-06-15 Chong Kun Dang Pharmaceutical Corp. Derivados de 3-(2-aril-cicloalquenilmetil)-oxazolidin-2-ona como inhibidores de la proteína de transferencia de ésteres de colesterol (CETP)
PL2729142T3 (pl) * 2011-07-08 2018-10-31 Novartis Ag Sposób leczenia miażdżycy tętnic u osobników z wysokim poziomem triglicerydów
WO2014119947A1 (en) 2013-01-31 2014-08-07 Chong Kun Dang Pharmaceutical Corp. Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors
JP2016535726A (ja) * 2013-11-11 2016-11-17 ロンザ・リミテッド ルイス酸を用いて第１３族のシアノ化合物を調製するための方法
SI3180314T1 (sl) * 2014-08-12 2022-11-30 Newamsterdam Pharma B.V. Postopek za pripravo sintetičnih intermediatov za pripravo derivatov tetrahidrokinolina
CN105294559B (zh) * 2015-06-24 2017-11-14 厦门法茉维特动物药业有限公司 一种医药中间体4‑氨基喹啉类化合物的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE316532T1 (de) 1998-07-10 2006-02-15 Massachusetts Inst Technology Liganden für metalle und metall-katalysiertes verfahren
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.

Also Published As

Publication number Publication date
KR100591998B1 (ko) 2006-06-22
CN1267411C (zh) 2006-08-02
US20020177716A1 (en) 2002-11-28
WO2002088069A9 (en) 2003-12-04
AR036331A1 (es) 2004-09-01
BR0209238A (pt) 2004-06-15
KR20040030603A (ko) 2004-04-09
RU2259355C2 (ru) 2005-08-27
US6689897B2 (en) 2004-02-10
DE60209004D1 (de) 2006-04-13
CN1297541C (zh) 2007-01-31
MXPA03009936A (es) 2004-01-29
JP3924251B2 (ja) 2007-06-06
HU225777B1 (en) 2007-08-28
PL366584A1 (en) 2005-02-07
YU84303A (sh) 2006-05-25
CA2445623A1 (en) 2002-11-07
CN1505609A (zh) 2004-06-16
CZ20032898A3 (cs) 2004-07-14
HUP0304039A3 (en) 2005-10-28
US6706881B2 (en) 2004-03-16
WO2002088085A2 (en) 2002-11-07
HUP0304039A2 (hu) 2004-03-29
ZA200306599B (en) 2004-10-22
RU2003131871A (ru) 2005-04-10
EP1425270A2 (de) 2004-06-09
AR035963A1 (es) 2004-07-28
IL157546A0 (en) 2004-03-28
AU2002253448B2 (en) 2007-07-05
HUP0304041A3 (en) 2005-08-29
DK1383734T3 (da) 2006-05-15
BR0209291A (pt) 2004-07-13
WO2002088069A2 (en) 2002-11-07
HK1062294A1 (en) 2004-10-29
JP3924250B2 (ja) 2007-06-06
US20030216576A1 (en) 2003-11-20
US20030073843A1 (en) 2003-04-17
ES2256461T3 (es) 2006-07-16
RU2003131870A (ru) 2005-01-27
CZ20032900A3 (cs) 2004-06-16
PL366700A1 (en) 2005-02-07
KR20040015200A (ko) 2004-02-18
EP1383734B1 (de) 2006-02-01
YU84403A (sh) 2006-08-17
JP2004531541A (ja) 2004-10-14
IL157544A0 (en) 2004-03-28
ZA200306600B (en) 2004-08-25
EP1425270B1 (de) 2006-03-29
ES2259080T3 (es) 2006-09-16
CA2445693A1 (en) 2002-11-07
EP1383734A2 (de) 2004-01-28
CN100357265C (zh) 2007-12-26
PT1425270E (pt) 2006-07-31
DE60210265T2 (de) 2006-10-12
DE60209004T2 (de) 2006-09-28
WO2002088069A3 (en) 2003-02-20
AR044706A2 (es) 2005-09-21
TWI250974B (en) 2006-03-11
MXPA03009935A (es) 2004-01-29
JP2004527556A (ja) 2004-09-09
CN1529696A (zh) 2004-09-15
WO2002088085A3 (en) 2004-03-25
KR100639745B1 (ko) 2006-10-30
RU2265010C2 (ru) 2005-11-27
HUP0304041A2 (hu) 2004-04-28
ATE316957T1 (de) 2006-02-15
CN1680292A (zh) 2005-10-12
DE60210265D1 (de) 2006-05-18
ATE321755T1 (de) 2006-04-15
US6600045B2 (en) 2003-07-29

Similar Documents

Publication Publication Date Title
DK1425270T3 (da) Fremgangsmåder og intermediater til fremstilling af 4-aminoquinolin CETP inhibitorer
DK1644384T3 (da) Fremgangsmåde og mellemprodukter til syntese af entecavir
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
DK1499594T3 (da) Fremgangsmåde til fremstilling af 7-substituerede 3-quinolin- og 3-quinol-4-on-carbonitriler
NO20033387D0 (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
DK2517706T3 (da) Fremgangsmåder og forbindelser til produktion af dipeptidylpeptidase iv-inhibitorer og mellemprodukter deraf
DK2574662T3 (da) Fremgangsmåde til elektroporation af biologiske prøver
DE60221977D1 (de) Pro-pharmakon von cox-2-inhibitoren
DK1360152T3 (da) Fremgangsmåde og indretning til fremstilling af mineraluld
DK1044969T3 (da) Fremgangsmåde og mellemprodukter til fremstilling af anti-cancer forbindelser
NO20033383L (no) Rörfört stablebart perforeringskanonsystem og fremgangsmåte for bruk
DK1328538T3 (da) Fremgangsmåde og mellemprodukter til fremstilling af 7-substituerede antiöstrogener
NO20033854L (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
DK1458447T3 (da) Kombination af cytokrom-p450-beroende proteasinhibitorer
DK1892239T3 (da) Inhibitorer af cytosol-phospholipase A2
DK1432683T3 (da) Hidtil ukendte krystallinske polymorfe former af lercanidipinhydrochlorid og fremgangsmåder til fremstilling heraf
DK1414492T3 (da) Fremgangsmåde til behandling af multipel myeloma
ITMI20021391A1 (it) Nitroderivati di inibitori della cicloossigenasi-2
NO20033506D0 (no) Parasittdrepende preparater og fremgangsmåter for anvendelse
DK1294659T3 (da) Fremgangsmåde til isolering af katamin
DK1487790T3 (da) Renset lasofoxifen og fremgangsmåde til opensning af racemisk lasofoxifen ved omkrystallisering
DK1400522T3 (da) Forbindelser til behandling af impotens
DK1802571T3 (da) Fremgangsmåde og mellemprodukter til fremstilling af derivater af N-(1-benzhydryl-azetidin-3-yl)- N-phenyl-methylsulfonamid
DK1311679T3 (da) Fremgangsmåde til inhibering af IL-22-induceret PAP1
DK1254159T3 (da) Fremgangsmåde til fremstilling af acetylamidiniophenylalanylcyclohexylglycylpyridylalaninamider